The present data support the hypothesis that ERBB2 amplification and/or overexpression enhance signalling pathways that may lead to increased production of gelatinases in c-erbB-2-positive breast cancers with higher metastatic potentialities. Here, ERBB2 is linked to breast carcinoma.